Assertio (ASRT)
(Real Time Quote from BATS)
$1.23 USD
-0.07 (-5.39%)
Updated Sep 23, 2024 11:53 AM ET
4-Sell of 5 4
C Value C Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Assertio Holdings, Inc. [ASRT]
Reports for Purchase
Showing records 1 - 20 ( 120 total )
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Project Rolvedon Sales Growth To More Than Offsets Indocin Declines From Exclusivity Loss Starting In 2025
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
2Q:24 Revenue Beat On Continued Rolvedon Sales Growth
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Modest Top-Line Beat; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
The Comeback Kid; Strength in Specialty Pharma; Initiating at Buy and $4 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Expect Revenue And Earnings To Rebound In 2025 On Increased Demand For Rolvedon,Maintain $3 Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
1Q:24 Revenue Beat On Rolvedon Sales; 2024 Sales Guidance Reiterated
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Project 1Q:24 Revenue Fell 32% From 1Q:23, Due To The Decline In Indocin Sales
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
4Q:23 Revenue Beat On Rolvedon Sales; 2024 Sales Guidance Issued
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Project 4Q:23 Revenue Fell 38% From 4Q:22, Due To The Decline In Indocin Sales From Exclusivity Loss
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
New CEO Announced; Lower Estimates, Reduce Price Target To $3
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Lower Estimates And Target To $4 (From $7);Expect 2025 Earnings Rebound; Balance Sheet Solid
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
3Q23 Recap - Hitting the Reset Button; Balance Sheet Helps
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Project 3Q:23 Revenue Jumped 36% As Rolvedon Launch More Than Offset Indocin Decline From Exclusivity Loss; Maintain $7 Price Target
Provider: Sidoti CSR
Analyst: Research Department
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Company: Assertio Holdings, Inc.
Industry: Medical - Drugs
Analyst Coverage Transition To James Sidoti; Spectrum Deal Complete
Provider: Sidoti CSR
Analyst: Research Department